Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
977 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (401)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06137274 | Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC | recruiting | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 |
| NCT06875609 | ctDNA in Cutaneous Squamous Cell Carcinoma | recruiting | — | 60 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07465276 | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07125755 | Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 386 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07481058 | KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer | recruiting | Phase 2 | 60 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07485296 | Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)(POST-BIO) | recruiting | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05539638 | The Role of Circulating Tumour DNA in Head and Neck Cancer | recruiting | — | 250 | University of EdinburghOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06211335 | Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 24 | University of California, DavisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07457528 | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06223659 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | recruiting | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT05901545 | Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer | recruiting | Phase 1 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05919290 | HN-QUEST: A Study of Head and Neck Imaging Biomarkers(HN-Quest) | recruiting | N/A | 173 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04857528 | Detecting HPV DNA in Anal and Cervical Cancers | recruiting | — | 20 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05526924 | Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer | recruiting | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07348887 | Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer(RTL-DART) | recruiting | N/A | 50 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca(MINIMA) | recruiting | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07444281 | An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer | recruiting | Phase 1 | 24 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07039162 | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 45 | Ming-Yu LienOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435376 | Intra-lesional Tumor Boost for Bulky Cervical Cancer(INTLECTUAL) | recruiting | Phase 2 | 17 | Seoul National University Bundang HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435454 | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437898 | Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study | recruiting | Phase 2 | 42 | The Affiliated Hospital of Putian UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06336941 | "Ultra-High Frequency intraOral UltraSonography of the TONgue" (HOUSTON)(HOUSTON) | recruiting | N/A | 400 | University of PisaOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06678724 | Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip | recruiting | — | 30 | National Taiwan University HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05031910 | Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality | recruiting | N/A | 160 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07288073 | TIL Therapy in cSCC and MCC | recruiting | Phase 2 | 14 | Karam Khaddour, MD, MSOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07405645 | Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy(MRg-FUS) | recruiting | N/A | 20 | University of VirginiaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402525 | Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial(PORT-ESTER) | recruiting | N/A | 190 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402616 | Ex Vivo Cutaneous SCC | recruiting | N/A | 30 | Rigshospitalet, DenmarkOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01473784 | Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck | recruiting | N/A | 600 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04099290 | Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | — | 50 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05962242 | HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma(HN001) | recruiting | Phase 2 | 90 | University of VirginiaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05838391 | Adaptive Radiation in Anal Cancer | recruiting | N/A | 20 | Columbia UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07385001 | A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC | recruiting | Phase 1 / Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05894083 | A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) | recruiting | Phase 2 | 150 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2026source: clinicaltrials